Doug Williams’ Codiak Biosciences gets $61M Series B for exosome work
This closes out Codiak Biosciences' Series B round first announced alongside its November launch - bringing the fledgling startup's funding to $92 million.
Former Biogen R&D head launches exosome-based biotech with $80M
Former Biogen R&D chief Doug Williams is launching a biotech startup called Codiak BioSciences with $80 million. It is developing exosomes as a new diagnostic and therapeutic tool, beginning with pancreatic cancer.
presented by
How to Improve Employee Benefits While Reducing Insurance Costs
Balancing healthcare benefits and insurance costs requires research. From becoming a Difference Card member to offering wellness resources, there are many ways to improve healthcare at low cost.